SCOPUS 정보 검색 플랫폼

Journal of Clinical Oncology

Volumn 28, Issue 32, 2010, Pages

What is the value of the 21-gene recurrence score?

(4) Brauchli, Peter a Thürlimann, Beat a,b Crowe, Susanne N a Herrmann, Richard a,c

a SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK (Switzerland)

b CANTONAL HOSPITAL ST GALLEN (Switzerland)

c UNIVERSITY HOSPITAL BASEL (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

21 GENE RECURRENCE SCORE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER THERAPY; HUMAN; LETTER; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; TREATMENT INDICATION; TUMOR GENE;

ANTINEOPLASTIC AGENTS; DECISION MAKING; GENE EXPRESSION PROFILING; HUMANS; RESEARCH;

EID: 79951894289 PISSN: 0732183X EISSN: 15277755 Source Type: Journal
DOI: 10.1200/JCO.2010.30.3313 Document Type: Letter

Times cited : (5)

References (6)

1
- 77950494285
- Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection
- Lo SS, Mumby PB, Norton J, et al: Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28:1671-1676, 2010
- (2010) J Clin Oncol , vol.28 , pp. 1671-1676
- Lo, S.S.¹ Mumby, P.B.² Norton, J.³

2
- 69449090120
- Thresholds for therapies: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
- Goldhirsch A, Ingle JN, Gelber RD, et al: Thresholds for therapies: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319-1329, 2009
- (2009) Ann Oncol , vol.20 , pp. 1319-1329
- Goldhirsch, A.¹ Ingle, J.N.² Gelber, R.D.³

3
- 0036916803
- The method of minimization for allocation to clinical trials: A review
- DOI 10.1016/S0197-2456(02)00242-8, PII S0197245602002428
- Scott NW, McPherson GC, Ramsay CR, et al: The method of minimization for allocation to clinical trials: A review. Control Clin Trials 23:662-674, 2002 (Pubitemid 36005476)
- (2002) Controlled Clinical Trials , vol.23 , Issue.6 , pp. 662-674
- Scott, N.W.¹ McPherson, G.C.² Ramsay, C.R.³ Campbell, M.K.⁴

4
- 58049196789
- Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-Year update of International Breast Cancer Study Group Trial 11-93
- Thürlimann B, Price KN, Gelber RD, et al: Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res Treat 113:137-144, 2009
- (2009) Breast Cancer Res Treat , vol.113 , pp. 137-144
- Thürlimann, B.¹ Price, K.N.² Gelber, R.D.³

5
- 77955773511
- Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer
- Paridaens RJ, Gelber S, Cole BF, et al: Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 123:303-310, 2010
- (2010) Breast Cancer Res Treat , vol.123 , pp. 303-310
- Paridaens, R.J.¹ Gelber, S.² Cole, B.F.³

6
- 71249157771
- Adjuvant! When the new world meets the old world
- Huober J, Thürlimann B: Adjuvant! When the new world meets the old world. Lancet Oncol 10:1028-1029, 2009
- (2009) Lancet Oncol , vol.10 , pp. 1028-1029
- Huober, J.¹ Thürlimann, B.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.